Showing 3581-3590 of 7510 results for "".
- Study Links Psoriasis Severity to Increased Heart Disease Riskhttps://practicaldermatology.com/news/study-links-psoriasis-severity-increased-heart-disease-risk/2468660/Psoriasis severity is associated with increased cardiovascular risk, according to new research, with systemic inflammation functioning as a key mediator. Data from two cohorts—the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative (PACI) and the Stockholm Psoriasis Cohort (SP
- Acne Insights: Strategies and Solutions at 2024 SDPA Fallhttps://practicaldermatology.com/news/acne-insights-strategies-and-solutions-2024-sdpa-fall/2468634/The SDPA’s 22nd Annual Fall Dermatology Conference was held last week at the Fontainebleau in Las Vegas. Conference Medical Director Hilary Baldwin, MD, joined Shanna Miranti, MPAS, PA-C, in a discussion called “Acne Insights: Expert Strategies and Solutions from the Pros.” The presentatio
- Study: PLLA-SCA Induces Adipogenesis and Volumization of the Hip Dellhttps://practicaldermatology.com/news/study-plla-sca-induces-adipogenesis-and-volumization-hip-dell/2468575/Injecting poly-l-lactic acid (PLLA-SCA) is a safe and effective method for durable volumization and aesthetic improvement of the hip dell, and may promote adipogenesis and elastogenesis, according to a new study published in Dermatologic Surgery. “People have used Sculptra for years, but w
- Rademikibart 'Could Be Incredibly Important for Type 2'https://practicaldermatology.com/news/rademikibart-could-be-incredibly-important-type-2/2468551/A second-generation IL-4Rα inhibitor known as rademikibart shows promise for further elevating the standard of care for type 2 inflammatory conditions in the future, Dr. Christopher Bunick said during a presentation at the 44th Annual Fall Clinical Dermatology Conference. Dr. Bunick showed
- New AD Research Indicates 'New Standards of Care'https://practicaldermatology.com/news/new-ad-research-indicates-new-standards-care/2468544/The bar has been raised for atopic dermatitis (AD). That was the message in “Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis,” a presentation from Drs. Christopher Bunick, Brad Glick, and Alexandra Gol
- 'Me & My Inner Circle' Launches on World Psoriasis Dayhttps://practicaldermatology.com/news/me-my-inner-circle-launches-world-psoriasis-day/2468497/October 29 is World Psoriasis Day, and Almirall recognized the occasion by launching an awareness campaign called “Me & My Inner Circle,” with the support of the International Federation of Psoriasis Associations (IFPA), the company announced. The campaign features Alma, representing a
- ImmunoSkin Conference Explores Inflammatory Skin Conditionshttps://practicaldermatology.com/news/immunoskin-conference-explores-inflammatory-skin-conditions/2468494/The third annual ImmunoSkin conference was held October 26-27 in Barcelona, Spain, highlighting new therapeutic strategies and facilitating exchange about the biological mechanisms of psoriasis and atopic dermatitis through clinical case studies and expert debates. The event was hosted by
- 3 Oral JAK Inhibitors for Vitiligo 'Running to the Finish Line'https://practicaldermatology.com/news/3-oral-jak-inhibitors-vitiligo-running-finish-line/2468487/Recent data supporting the use of topical ruxolitinib and oral Janus kinase (JAK) inhibitors for treating vitiligo were presented by Dr. Seemal Desai and Dr. Larry Eichenfield at the 44th Annual Fall Clinical Dermatology Conference. In the TRuE-V1 and TRuE-V2 studies, for all body regions
- Dupilumab Improves Chronic Spontaneous Urticaria Symptomshttps://practicaldermatology.com/news/dupixent-improves-chronic-spontaneous-urticaria-symptoms/2468471/Dupixent® (dupilumab) significantly reduced itch and hive activity in patients with chronic spontaneous urticaria, according to phase 3 trial data presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting in Boston, Massachusetts. In a pre
- Study: Roflumilast cream 0.15% Significantly Reduces Itch, Improves Quality of Lifehttps://practicaldermatology.com/news/study-roflumilast-cream-015-significantly-reduces-itch-improves-quality-life/2468468/New data show that ZORYVE® (Roflumilast) cream 0.15% rapidly alleviates symptoms of atopic dermatitis (AD) and significantly improves patient-reported outcomes, including daily activity, sleep, and emotional well-being, according to Arcutis. The manufacturer announced in a pres